SPOTLIGHT: Wyeth sues Watson to quash generic


It's Watson Pharmaceuticals and Wyeth in the ring, as Watson filed for FDA approval to sell a generic version of Lybrel, a birth control pill, and Wyeth responded by suing for patent infringement. Report, Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.